nQ Medical is an artificial intelligence company that’s developed a computational biomarker that yields powerful insight. Everybody has a unique typing and touchscreen signature. How our fingers interact with computers can reveal with startling accuracy the presence of certain neuromotor diseases like Parkinson’s, Alzheimer’s, ALS, and Multiple Sclerosis. nQ has been proven in four years of clinical trials at MIT, backed by the Michael J. Fox Foundation, to substantially change the way disease is managed for a wide range of neuromotor and neurocognitive disorders. We also have ongoing studies with the Cleveland Clinic and Massachusetts General Hospital to expand nQ’s indications. We analyze user interaction with common, personal devices without capturing information that’s being typed or requiring any special hardware. The fine control of typing and touch screen kinematics, as well as the frequent use of these electronic devices brings real world data to clinicians. Beyond early detection, our AI technology supports clinical trials by improving accuracy and efficiency in recruitment, 24/7, passive monitoring of disease progression from home, and measuring the impact of therapy on outcomes at a far more granular level than current gold standards. What’s more, our platform provides unified data management across the entire lifecycle, from clinical trials to clinician dashboards, and from patient engagement to population health . There are many applications for our technology, currently these include:
nQ addresses the real challenges faced by clinical trials head on. Specifically, it helps with:
+ Remote, online recruitment of ideal study participants, by:
- Shrinking disease detection and recruitment time.
- Improving disease staging and patient targeting.
+ Dependence on in-clinic observation is reduced by relying on at-home, unbiased real-world data.
+ Shaping treatment pathways for neurodegenerative diseases with the earliest measure of therapeutic impact, thanks to passive, continuous monitoring of patients.
Disease Progression and Therapeutic Efficacy Measurement Platform. nQ is a valuable prescription companion in many forms. It can be deployed as:
+ A Mobile Management App for Parkinson’s Disease
- A powerful remote disease progression and therapy measurement tool, used with outpatient treatment, under the guidance of a healthcare professional, and in conjunction with a drug or device.
+ A digital health device that supports medication-assisted treatment for:
- Clinical titration decisions, and
- A tool for patient engagement and adherence as well as caregiver observation.
+ A direct download to patient’s mobile device after prescription.
- Used in conjunction with a clinician-supervised outpatient treatment protocol.
nQ Medical are proud supporters of the AI Applications in Biopharma Summit